The Mucin Paradox: Decoding the Molecular Strategies of Akkermansia muciniphila in Health and Disease

Akkermansia muciniphila is a next-generation probiotic linked to intestinal barrier integrity and host metabolic well-being. However, the mechanisms underlying its mucin utilization remain incompletely understood. In particular, the temporal hierarchy of enzyme deployment, the subcellular and extracellular-vesicle localization of individual mucin-degrading enzymes (MDEs), the fine substrate specificity of glycoside hydrolases toward distinct O-glycan linkages, and the strain-dependent differences in mucinolytic capacity have yet to be resolved. This review integrates genomic, biochemical, and metabolic data to show how A. muciniphila mucin-degrading enzymes (MDEs) degrade mucus, releasing nutrients that support A. muciniphila growth and fermentation (acetate and propionate) and cross-feeding by other bacteria, including butyrate producers. It also highlights that A. muciniphila exhibits a dual nature: it safely stimulates regulated mucus degradation, improves barrier integrity, and feeds beneficial microbes. In contrast, in specific experimental contexts, such as fiber-deprived or high-sugar murine models, dietary fiber shortage or metabolic stress has been associated with increased mucus degradation, a thinner mucus layer, and greater susceptibility to inflammation and pathogens. The probiotic effects of A. muciniphila against metabolic and inflammatory conditions may involve regulated mucin degradation, but benefits may also arise from mechanisms beyond active mucin degradation, including bacterial surface proteins and pasteurized preparations. Unlocking the safe therapeutic potential of this bacterium requires mapping out the spatial, temporal, and strain-specific details of these enzymes. Future research should combine multi-omics and host-interaction studies to clarify enzyme hierarchy, vesicle delivery, and context-dependent impacts.